163 related articles for article (PubMed ID: 22982181)
1. Co-expression of estrogen receptor beta and aromatase in Japanese lung cancer patients: gender-dependent clinical outcome.
Verma MK; Miki Y; Abe K; Nagasaki S; Niikawa H; Suzuki S; Kondo T; Sasano H
Life Sci; 2012 Oct; 91(15-16):800-8. PubMed ID: 22982181
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.
Niikawa H; Suzuki T; Miki Y; Suzuki S; Nagasaki S; Akahira J; Honma S; Evans DB; Hayashi S; Kondo T; Sasano H
Clin Cancer Res; 2008 Jul; 14(14):4417-26. PubMed ID: 18579664
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic estrogen receptor β as a potential marker in human non-small cell lung carcinoma.
Verma MK; Miki Y; Abe K; Niikawa H; Sasano H
Expert Opin Ther Targets; 2012 Mar; 16 Suppl 1():S91-102. PubMed ID: 22313325
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer.
Skjefstad K; Grindstad T; Khanehkenari MR; Richardsen E; Donnem T; Kilvaer T; Andersen S; Bremnes RM; Busund LT; Al-Saad S
Steroids; 2016 Sep; 113():5-13. PubMed ID: 27234503
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
6. Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancer.
Mah V; Marquez D; Alavi M; Maresh EL; Zhang L; Yoon N; Horvath S; Bagryanova L; Fishbein MC; Chia D; Pietras R; Goodglick L
Lung Cancer; 2011 Nov; 74(2):318-25. PubMed ID: 21511357
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors in human lung cancer therapy.
Weinberg OK; Marquez-Garban DC; Fishbein MC; Goodglick L; Garban HJ; Dubinett SM; Pietras RJ
Cancer Res; 2005 Dec; 65(24):11287-91. PubMed ID: 16357134
[TBL] [Abstract][Full Text] [Related]
8. Intratumoral localization and activity of 17β-hydroxysteroid dehydrogenase type 1 in non-small cell lung cancer: a potent prognostic factor.
Verma MK; Miki Y; Abe K; Suzuki T; Niikawa H; Suzuki S; Kondo T; Sasano H
J Transl Med; 2013 Jul; 11():167. PubMed ID: 23837683
[TBL] [Abstract][Full Text] [Related]
9. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer.
Abe K; Miki Y; Ono K; Mori M; Kakinuma H; Kou Y; Kudo N; Koguchi M; Niikawa H; Suzuki S; Evans DB; Sugawara S; Suzuki T; Sasano H
Hum Pathol; 2010 Feb; 41(2):190-8. PubMed ID: 19800101
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral concentration of estrogens and clinicopathological changes in ductal carcinoma in situ following aromatase inhibitor letrozole treatment.
Takagi K; Ishida T; Miki Y; Hirakawa H; Kakugawa Y; Amano G; Ebata A; Mori N; Nakamura Y; Watanabe M; Amari M; Ohuchi N; Sasano H; Suzuki T
Br J Cancer; 2013 Jul; 109(1):100-8. PubMed ID: 23756858
[TBL] [Abstract][Full Text] [Related]
11. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
12. Smoking out reproductive hormone actions in lung cancer.
Siegfried JM
Mol Cancer Res; 2014 Jan; 12(1):24-31. PubMed ID: 24398390
[TBL] [Abstract][Full Text] [Related]
13. In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Lykkesfeldt AE; Henriksen KL; Rasmussen BB; Sasano H; Evans DB; Møller S; Ejlertsen B; Mouridsen HT
BMC Cancer; 2009 Jun; 9():185. PubMed ID: 19531212
[TBL] [Abstract][Full Text] [Related]
14. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S
Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral localization of aromatase and interaction between stromal and parenchymal cells in the non-small cell lung carcinoma microenvironment.
Miki Y; Suzuki T; Abe K; Suzuki S; Niikawa H; Iida S; Hata S; Akahira J; Mori K; Evans DB; Kondo T; Yamada-Okabe H; Sasano H
Cancer Res; 2010 Aug; 70(16):6659-69. PubMed ID: 20710045
[TBL] [Abstract][Full Text] [Related]
16. Targeting aromatase and estrogen signaling in human non-small cell lung cancer.
Márquez-Garbán DC; Chen HW; Goodglick L; Fishbein MC; Pietras RJ
Ann N Y Acad Sci; 2009 Feb; 1155():194-205. PubMed ID: 19250205
[TBL] [Abstract][Full Text] [Related]
17. Suppression of estrogen actions in human lung cancer.
Miki Y; Abe K; Suzuki S; Suzuki T; Sasano H
Mol Cell Endocrinol; 2011 Jul; 340(2):168-74. PubMed ID: 21354461
[TBL] [Abstract][Full Text] [Related]
18. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands.
Hershberger PA; Vasquez AC; Kanterewicz B; Land S; Siegfried JM; Nichols M
Cancer Res; 2005 Feb; 65(4):1598-605. PubMed ID: 15735050
[TBL] [Abstract][Full Text] [Related]
19. ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Wang Z; Li Z; Ding X; Shen Z; Liu Z; An T; Duan J; Zhong J; Wu M; Zhao J; Zhuo M; Wang Y; Wang S; Sun Y; Bai H; Wang J
Sci Rep; 2015 Jun; 5():11392. PubMed ID: 26096604
[TBL] [Abstract][Full Text] [Related]
20. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
